Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.96) by 23.96 percent. This is a 58.67 percent decrease over losses of $(0.75) per share from the same period last year.